Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 54 | 2024 | 21162 | 2.780 |
Why?
|
Immunoconjugates | 9 | 2024 | 969 | 1.790 |
Why?
|
Cyclin-Dependent Kinase 4 | 9 | 2023 | 566 | 1.760 |
Why?
|
Cyclin-Dependent Kinase 6 | 7 | 2022 | 354 | 1.700 |
Why?
|
Camptothecin | 6 | 2024 | 593 | 1.350 |
Why?
|
Neoadjuvant Therapy | 12 | 2023 | 2909 | 1.300 |
Why?
|
Protein Kinase Inhibitors | 9 | 2023 | 5708 | 0.870 |
Why?
|
Receptor, erbB-2 | 14 | 2024 | 2588 | 0.850 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 17 | 2024 | 11854 | 0.760 |
Why?
|
Indazoles | 1 | 2022 | 305 | 0.710 |
Why?
|
Receptors, Estrogen | 10 | 2024 | 2247 | 0.690 |
Why?
|
Aminopyridines | 6 | 2021 | 580 | 0.530 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2021 | 1536 | 0.460 |
Why?
|
Cell Cycle | 3 | 2023 | 2938 | 0.440 |
Why?
|
Piperidines | 1 | 2022 | 1659 | 0.440 |
Why?
|
Carcinoma | 2 | 2023 | 2341 | 0.440 |
Why?
|
Neutropenia | 2 | 2017 | 893 | 0.420 |
Why?
|
Standard of Care | 1 | 2017 | 570 | 0.410 |
Why?
|
Purines | 5 | 2019 | 615 | 0.400 |
Why?
|
Retinoblastoma Protein | 1 | 2016 | 673 | 0.400 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2021 | 3553 | 0.390 |
Why?
|
Drug Resistance, Neoplasm | 8 | 2024 | 5336 | 0.370 |
Why?
|
Estrogen Receptor alpha | 4 | 2024 | 581 | 0.340 |
Why?
|
Ketones | 2 | 2021 | 182 | 0.340 |
Why?
|
Furans | 2 | 2021 | 201 | 0.340 |
Why?
|
Female | 61 | 2024 | 397089 | 0.330 |
Why?
|
Receptors, Progesterone | 4 | 2021 | 1145 | 0.320 |
Why?
|
Antineoplastic Agents | 7 | 2023 | 13697 | 0.310 |
Why?
|
Molecular Targeted Therapy | 3 | 2024 | 2830 | 0.300 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 1600 | 0.290 |
Why?
|
Humans | 72 | 2024 | 768393 | 0.280 |
Why?
|
Disease-Free Survival | 5 | 2021 | 6856 | 0.260 |
Why?
|
Telemedicine | 1 | 2023 | 3107 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2024 | 9433 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3118 | 0.250 |
Why?
|
Mammography | 1 | 2016 | 2434 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3241 | 0.250 |
Why?
|
Mass Screening | 2 | 2020 | 5451 | 0.240 |
Why?
|
Benzimidazoles | 2 | 2021 | 864 | 0.230 |
Why?
|
Educational Measurement | 1 | 2011 | 1256 | 0.230 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.230 |
Why?
|
Patient Readmission | 2 | 2016 | 3312 | 0.230 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1905 | 0.210 |
Why?
|
Neoplasm Metastasis | 8 | 2024 | 4921 | 0.200 |
Why?
|
Education, Medical, Undergraduate | 1 | 2011 | 1082 | 0.200 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1019 | 0.200 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 628 | 0.190 |
Why?
|
Clinical Trials as Topic | 6 | 2021 | 8051 | 0.190 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2017 | 5713 | 0.170 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 330 | 0.170 |
Why?
|
Breast Neoplasms, Male | 1 | 2021 | 212 | 0.160 |
Why?
|
Antigens, Neoplasm | 2 | 2024 | 1999 | 0.160 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2024 | 957 | 0.160 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 640 | 0.150 |
Why?
|
Gene Fusion | 1 | 2021 | 356 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 259 | 0.150 |
Why?
|
Students, Medical | 1 | 2011 | 1964 | 0.150 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2024 | 2884 | 0.140 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 102 | 0.140 |
Why?
|
Prognosis | 7 | 2024 | 30022 | 0.140 |
Why?
|
Middle Aged | 20 | 2024 | 223491 | 0.130 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2018 | 506 | 0.130 |
Why?
|
Treatment Outcome | 8 | 2024 | 65379 | 0.130 |
Why?
|
Piperazines | 4 | 2020 | 2552 | 0.130 |
Why?
|
Fluorouracil | 1 | 2020 | 1655 | 0.120 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11254 | 0.120 |
Why?
|
Paclitaxel | 2 | 2023 | 1736 | 0.120 |
Why?
|
BRCA2 Protein | 1 | 2020 | 802 | 0.120 |
Why?
|
Mastectomy | 2 | 2021 | 1851 | 0.120 |
Why?
|
Signal Transduction | 3 | 2024 | 23631 | 0.120 |
Why?
|
Hypothermia, Induced | 1 | 2020 | 756 | 0.120 |
Why?
|
Postmenopause | 3 | 2019 | 2518 | 0.120 |
Why?
|
Pilot Projects | 3 | 2023 | 8731 | 0.120 |
Why?
|
Histone Deacetylases | 1 | 2019 | 717 | 0.120 |
Why?
|
Stomatitis | 1 | 2017 | 271 | 0.120 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2016 | 305 | 0.110 |
Why?
|
Quality of Life | 4 | 2022 | 13503 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2020 | 573 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1628 | 0.110 |
Why?
|
BRCA1 Protein | 1 | 2020 | 1155 | 0.110 |
Why?
|
Autopsy | 1 | 2017 | 1013 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1614 | 0.110 |
Why?
|
Drug Interactions | 1 | 2017 | 1420 | 0.100 |
Why?
|
Mutation | 10 | 2024 | 30228 | 0.100 |
Why?
|
Retrospective Studies | 10 | 2024 | 81801 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1407 | 0.100 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2024 | 131 | 0.100 |
Why?
|
Age Factors | 3 | 2018 | 18471 | 0.100 |
Why?
|
Doxorubicin | 1 | 2018 | 2229 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2353 | 0.100 |
Why?
|
Pyridines | 3 | 2019 | 2889 | 0.100 |
Why?
|
Informed Consent | 1 | 2018 | 1010 | 0.100 |
Why?
|
Adult | 15 | 2024 | 223640 | 0.090 |
Why?
|
Aged | 16 | 2024 | 171562 | 0.090 |
Why?
|
Internship and Residency | 1 | 2011 | 5949 | 0.090 |
Why?
|
Forecasting | 1 | 2020 | 2948 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2023 | 3627 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2066 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8753 | 0.090 |
Why?
|
Phthalazines | 2 | 2024 | 397 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1448 | 0.080 |
Why?
|
Aromatase Inhibitors | 2 | 2024 | 519 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5375 | 0.080 |
Why?
|
Burns | 1 | 2020 | 1893 | 0.080 |
Why?
|
RNA | 1 | 2018 | 2726 | 0.080 |
Why?
|
Survival Rate | 3 | 2021 | 12870 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1901 | 0.080 |
Why?
|
Survival Analysis | 2 | 2017 | 10117 | 0.070 |
Why?
|
Neoplasms | 3 | 2022 | 22385 | 0.070 |
Why?
|
Lung Diseases | 1 | 2017 | 1925 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4907 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39407 | 0.070 |
Why?
|
Biopsy | 1 | 2018 | 6808 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2016 | 7861 | 0.060 |
Why?
|
Genomics | 4 | 2023 | 5916 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3941 | 0.060 |
Why?
|
Logistic Models | 2 | 2016 | 13323 | 0.060 |
Why?
|
Recurrence | 1 | 2017 | 8506 | 0.060 |
Why?
|
Schools, Medical | 1 | 2011 | 881 | 0.060 |
Why?
|
Estrogens | 2 | 2021 | 1534 | 0.060 |
Why?
|
Stroke Volume | 1 | 2018 | 5619 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7453 | 0.060 |
Why?
|
Decision Making | 1 | 2016 | 3953 | 0.050 |
Why?
|
Biomedical Research | 1 | 2018 | 3464 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3231 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 332 | 0.050 |
Why?
|
Motivation | 1 | 2011 | 2029 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8379 | 0.050 |
Why?
|
Receptor, erbB-3 | 1 | 2021 | 142 | 0.040 |
Why?
|
Hot Flashes | 1 | 2023 | 330 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 17135 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10377 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 906 | 0.040 |
Why?
|
Annexin A6 | 1 | 2018 | 4 | 0.040 |
Why?
|
United States | 3 | 2024 | 73150 | 0.040 |
Why?
|
Hormones | 1 | 2023 | 870 | 0.040 |
Why?
|
Risk Assessment | 1 | 2020 | 24318 | 0.040 |
Why?
|
Rifamycins | 1 | 1998 | 27 | 0.040 |
Why?
|
Depressive Disorder | 1 | 2011 | 3736 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2024 | 1614 | 0.040 |
Why?
|
Prospective Studies | 4 | 2023 | 54920 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 737 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 937 | 0.040 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2021 | 664 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
Androstadienes | 1 | 2019 | 348 | 0.040 |
Why?
|
Scalp | 1 | 2020 | 391 | 0.040 |
Why?
|
Pulmonary Veno-Occlusive Disease | 1 | 2017 | 64 | 0.030 |
Why?
|
Anxiety | 1 | 2011 | 4677 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2018 | 606 | 0.030 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 1998 | 366 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4039 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2021 | 1251 | 0.030 |
Why?
|
Fasting | 1 | 2022 | 1610 | 0.030 |
Why?
|
Alopecia | 1 | 2020 | 416 | 0.030 |
Why?
|
Clinical Competence | 1 | 2011 | 4848 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1105 | 0.030 |
Why?
|
Menopause | 1 | 2023 | 1653 | 0.030 |
Why?
|
Genotype | 2 | 2021 | 13042 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1555 | 0.030 |
Why?
|
Gene Amplification | 1 | 2019 | 1090 | 0.030 |
Why?
|
Risk Factors | 3 | 2018 | 74962 | 0.030 |
Why?
|
Graft vs Host Disease | 2 | 2017 | 3044 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2106 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13576 | 0.030 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2019 | 775 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59686 | 0.030 |
Why?
|
Young Adult | 2 | 2017 | 60049 | 0.030 |
Why?
|
Mice, Nude | 1 | 2018 | 3632 | 0.030 |
Why?
|
Breast | 1 | 2021 | 1975 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2023 | 5313 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4120 | 0.020 |
Why?
|
Depression | 1 | 2011 | 8241 | 0.020 |
Why?
|
Fear | 1 | 2020 | 1494 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2349 | 0.020 |
Why?
|
Social Support | 1 | 2020 | 2191 | 0.020 |
Why?
|
Male | 5 | 2021 | 364902 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1620 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 6006 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2952 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2017 | 4834 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4450 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8902 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3666 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41795 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 1998 | 1929 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7445 | 0.020 |
Why?
|
Adolescent | 1 | 2014 | 89184 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9562 | 0.020 |
Why?
|
Disease Progression | 1 | 2023 | 13646 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9261 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9510 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10776 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12456 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14481 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 22355 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 6670 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 1998 | 7463 | 0.010 |
Why?
|
Animals | 2 | 2024 | 169337 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21544 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1998 | 830 | 0.010 |
Why?
|
Child | 1 | 2023 | 80891 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 40272 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 1998 | 1479 | 0.010 |
Why?
|
Base Sequence | 1 | 1998 | 12422 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1998 | 17626 | 0.000 |
Why?
|